Drug General Information (ID: DDIO6K58WZ)
Drug Name			Metoprolol		Drug Info		Hydralazine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antihypertensive Agents				Antihypertensive Agents
Structure

Mechanism of Metoprolol-Hydralazine Interaction (Severity Level: Minor)
Interference with first-pass metabolism Click to Show/Hide Mechanism Graph
Drug Name		Metoprolol				Hydralazine
Mechanism		Extensive first-pass metabolism				Reduced hepatic blood flow
Key Mechanism Factor 1
		Factor Name		First-pass metabolism
		Factor Description		First-pass metabolism is a drug metabolism phenomenon in which the concentration of a drug, especially when administered orally, is greatly reduced before it reaches the systemic circulation. Interfering with the first-pass metabolism of a drug may affect the total amount of drug reaching the systemic circulation.
Mechanism Description		Decreased metabolism of Metoprolol caused by Hydralazine mediated interference with first-pass metabolism

References
1	Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21. [PMID: 1451723]
2	Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):.
3	Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40. [PMID: 1349528]
4	Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, Rames A, Lecocq B, Jaillon P "Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers." J Cardiovasc Pharmacol 18 (1991): 28-34. [PMID: 1719288]
5	Lindeberg S, Holm B, Lundborg P, Regardh CG, Sandstrom B "The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women." Eur J Clin Pharmacol 35 (1988): 131-5. [PMID: 3191932]
6	McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW "Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin." Clin Pharmacol Ther 38 (1985): 409-13. [PMID: 2864157]
7	McLean AJ, Skews H, Bobik A, Dudley FJ "Interaction between oral propranolol and hydralazine." Clin Pharmacol Ther 27 (1980): 726-32. [PMID: 7379440]
8	McLean AJ, Wilhelm D, Heinzow BG "Stable oral availability of atenolol coadministered with hydralazine. Comparison with propranolol, metoprolol and other B-Adrenoceptor antagonists." Drugs 25 (1983): 131-5.
9	McTavish D, Campoli-Richards D, Sorkin EM "Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy." Drugs 45 (1993): 232-58. [PMID: 7681374]
10	Morgan T "Clinical pharmacokinetics and pharmacodynamics of carvedilol." Clin Pharmacokinet 26 (1994): 335-46. [PMID: 7914479]
11	Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F "Effect of aging on the pharmacokinetics of acebutolol enantiomers." J Clin Pharmacol 32 (1992): 148-56. [PMID: 1613125]
12	Product Information. Betapace (sotalol). Berlex, Richmond, CA.
13	Product Information. Blocadren (timolol). Merck & Co, Inc, West Point, PA.
14	Product Information. Brevibloc (esmolol). DuPont Pharmaceuticals, Wilmington, DE.
15	Product Information. Cartrol (carteolol). Abbott Pharmaceutical, Abbott Park, IL.
16	Product Information. Corgard (nadolol). Bristol-Myers Squibb, Princeton, NJ.
17	Product Information. Inderal (propranolol). Wyeth-Ayerst Laboratories, Philadelphia, PA.
18	Product Information. Levatol (penbutolol). Reed and Carnrick, Jersey City, NJ.
19	Product Information. Normodyne (labetalol). Schering Laboratories, Kenilworth, NJ.
20	Product Information. Tenormin (atenolol). ICN Pharmaceuticals Inc, Cost Mesa, CA.
21	Schneck DW, Vary JE "Mechanism by which hydralazine increases propranolol bioavailability." Clin Pharmacol Ther 35 (1984): 447-53. [PMID: 6705442]
22	Desmedt S, Spinewine A, Jadoul M, Henrard S, Wouters D, Dalleur O. Impact of a clinical decision support system for drug dosage in patients with renal failure.?Int J Clin Pharm. 2018;40(5):1225-1233. [PMID: 29785684]
23	Smith RL "Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance." Eur J Clin Pharmacol 28 (1985): 77-84. [PMID: 2865154]
24	Stagni G, Davis PJ, Ludden TM "Human pharmacokinetics of betaxolol enantiomers." J Pharm Sci 80 (1991): 321-4. [PMID: 1865331]
25	Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ "Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions." Br J Clin Pharmacol 17 Suppl (1984): s45-50. [PMID: 6743474]